Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Rhea-AI Summary

Day One Biopharmaceuticals (DAWN) has announced it will host a conference call and webcast on Tuesday, February 25, 2025, at 4:30 p.m. ET to discuss its fourth quarter and full-year 2024 financial results and corporate progress. The live audio webcast will be available on the company's Investors & Media page, with a replay accessible for 30 days following the event in the Events & Presentations section.

BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2024.

Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days following the event.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage company focused on advancing first- or best-in-class medicines for childhood and adult diseases with equal intensity. We were founded to address the lack of new therapies resulting from the traditional drug development model, which has left children with cancer and their families waiting too long for new treatments.

At Day One, we aim to identify and develop breakthrough medicines with the goal of improving the outcomes and life trajectories of patients of any age facing serious diseases — starting from Day One. Our “search & development” strategy enables us to find, acquire, and develop potential best-or first-in-class programs with the goal of introducing new medicines that will make a real difference in the treatment of children and adults.

Day One’s pipeline includes tovorafenib (OJEMDA™), DAY301 and a VRK1 inhibitor program. The Company is based in Brisbane, California and can be found online at www.dayonebio.com, LinkedIn or X.

Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com

DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com

FAQ

When will Day One Biopharmaceuticals (DAWN) report Q4 and full-year 2024 earnings?

Day One Biopharmaceuticals will report its Q4 and full-year 2024 earnings on Tuesday, February 25, 2025, at 4:30 p.m. ET.

How can investors access DAWN's Q4 2024 earnings call?

Investors can access the live audio webcast through Day One's Investors & Media page on their website.

How long will DAWN's Q4 2024 earnings call replay be available?

The earnings call replay will be available for 30 days following the event in the Events & Presentations section of Day One's Investors & Media page.

What will be discussed in Day One Biopharmaceuticals' (DAWN) upcoming earnings call?

The earnings call will cover financial results and corporate progress for the fourth quarter and full-year 2024.